Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
The Permanente Journal
|
June 11, 2011
Evidence-based guidelines
Paul H Barrett, Grant Okawa, Jill Bowman
The Clinical Teacher
|
May 27, 2015
Teaching high-value care: a novel morning report
Jill Bowman, Alisa Duran, Briar Duffy, et al.
Frontiers in Oncology
|
September 12, 2022
POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma
Sheela Rao, Mark Jones, Jill Bowman, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study
Naresh Punwani, Swamy Yeleswaram, Xuejun Chen, et al.
Postgraduate Medicine
|
August 9, 2020
Communicating value to patients-a high-value care communication skills curriculum
Alisa Duran, Crystal Donelan, Jill Bowman Peterson, et al.
Health Affairs (Project Hope)
|
September 11, 2008
The potential effects of HEDIS performance measures on the quality of care
David M Eddy, L Gregory Pawlson, David Schaaf, et al.
Gynecologic Oncology
|
June 2, 2024
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study
Dominique Berton, Patricia Pautier, Domenica Lorusso, et al.
Virology
|
May 3, 2011
Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein
Melinda A Brindley, Catherine L Hunt, Andrew S Kondratowicz, et al.
Cancer Research Communications
|
December 20, 2023
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Pamela Munster, Nicholas Iannotti, Daniel C Cho, et al.
Cancer Research Communications
|
March 13, 2024
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Pamela Munster, Nicholas Iannotti, Daniel C Cho, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
The Permanente Journal
|
June 11, 2011
Evidence-based guidelines
Paul H Barrett, Grant Okawa, Jill Bowman
The Clinical Teacher
|
May 27, 2015
Teaching high-value care: a novel morning report
Jill Bowman, Alisa Duran, Briar Duffy, et al.
Frontiers in Oncology
|
September 12, 2022
POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma
Sheela Rao, Mark Jones, Jill Bowman, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study
Naresh Punwani, Swamy Yeleswaram, Xuejun Chen, et al.
Postgraduate Medicine
|
August 9, 2020
Communicating value to patients-a high-value care communication skills curriculum
Alisa Duran, Crystal Donelan, Jill Bowman Peterson, et al.
Health Affairs (Project Hope)
|
September 11, 2008
The potential effects of HEDIS performance measures on the quality of care
David M Eddy, L Gregory Pawlson, David Schaaf, et al.
Gynecologic Oncology
|
June 2, 2024
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study
Dominique Berton, Patricia Pautier, Domenica Lorusso, et al.
Virology
|
May 3, 2011
Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein
Melinda A Brindley, Catherine L Hunt, Andrew S Kondratowicz, et al.
Cancer Research Communications
|
December 20, 2023
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Pamela Munster, Nicholas Iannotti, Daniel C Cho, et al.
Cancer Research Communications
|
March 13, 2024
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Pamela Munster, Nicholas Iannotti, Daniel C Cho, et al.
Page
of 1